Radiosurgery plus standard care for lung cancer spread to brain
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests if adding stereotactic radiosurgery (focused radiation) to standard drug therapy is safe and effective for people with EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to improve control of brain metastases while continuing targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer with an EGFR mutation confirmed by your hospital.
- You have at least one brain tumor seen on an MRI before starting your targeted therapy drug.
- You have not started targeted therapy yet, or you started it within the last 3 months and have a brain MRI from before you started.
- You cannot have had radiation to the brain before, or have cancer spread to the lining of the brain or spinal cord.
- If you are of childbearing potential, you must use highly effective birth control during the study and for 3 months after the last treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
This trial tests adding a brain-sparing radiation technique to the targeted therapy drug osimertinib for people with EGFR-mutant lung adenocarcinoma that has spread to the brain and is causing symptoms. The goal is to see if this combination can better control the brain tumors while protecting the hippocampus, a key memory area.
This Phase 2 trial tests a type of focused radiation (stereotactic radiosurgery, or SRS) for people with small cell lung cancer that has spread to the brain. It looks at whether this approach can treat brain metastases when the cancer has limited to a certain number of spots.
This trial tests a combination of radiation to the brain plus chemotherapy and immunotherapy (anti-PD-1/PD-L1) for people with newly diagnosed non-small cell lung cancer that has spread to the brain. It is for those whose tumors do not have common driver mutations and whose brain metastases are causing symptoms.
This trial tests a new way to deliver radiation to brain metastases from non-small cell lung cancer, using MRI scans to guide the treatment and reduce the area exposed. The goal is to see if this approach is safe and effective while possibly lowering side effects.
This trial tests if adding targeted radiation to a combination of immunotherapy (Ivonescimab) and chemotherapy works better than the drugs alone for people with non-small cell lung cancer (NSCLC) that has spread to the brain. It is for patients who have not had prior treatment for their advanced lung cancer.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.